Literature DB >> 12547611

Evaluation of adjuvants for protein vaccines against tuberculosis in guinea pigs.

Philip J Hogarth1, Keith J Jahans, Rolf Hecker, R Glyn Hewinson, Mark A Chambers.   

Abstract

Subunit vaccines against tuberculosis show promise but require administration with adjuvants to stimulate relevant immune responses for protection. Guinea pigs are the model of choice for evaluating protective immunity to aerogenic challenge with virulent mycobacteria, but few studies have been undertaken to identify suitable adjuvants for vaccine screening in this species. Here, we compare the efficacy of several adjuvants to induce T cell responses to culture filtrate protein in guinea pigs. We report that of several adjuvants tested, the most promising was CpG ODN formulated in an aqueous emulsion. This adjuvant induced type 1 T cell responses equivalent to that of FIA, as measured by delayed-type hypersensitivity reactions (DTH), antigen-specific T cell proliferation and antigen-specific IgG1 and IgG2 responses. These data demonstrate the potential for CpG motif based adjuvants for use in TB vaccine screening in guinea pigs, and other diseases where a type 1 T cell response is required.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12547611     DOI: 10.1016/s0264-410x(02)00548-0

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  8 in total

1.  Antibody responses elicited through homologous or heterologous prime-boost DNA and protein vaccinations differ in functional activity and avidity.

Authors:  Michael Vaine; Shixia Wang; Anthony Hackett; James Arthos; Shan Lu
Journal:  Vaccine       Date:  2010-02-17       Impact factor: 3.641

2.  Efficient protein boosting after plasmid DNA or recombinant adenovirus immunization with HIV-1 vaccine constructs.

Authors:  Yuuei Shu; Sarah Winfrey; Zhi-Yong Yang; Ling Xu; Srinivas S Rao; Indresh Srivastava; Susan W Barnett; Gary J Nabel; John R Mascola
Journal:  Vaccine       Date:  2006-11-07       Impact factor: 3.641

3.  Induction of neutralizing antibodies against human immunodeficiency virus type 1 primary isolates by Gag-Env pseudovirion immunization.

Authors:  Jason Hammonds; Xuemin Chen; Timothy Fouts; Anthony DeVico; David Montefiori; Paul Spearman
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

4.  Increased levels of interferon-gamma primed by culture filtrate proteins antigen and CpG-ODN immunization do not confer significant protection against Mycobacterium tuberculosis infection.

Authors:  Denise Morais da Fonseca; Célio Lopes Silva; Marina Oliveira e Paula; Edson Garcia Soares; Gilles Marchal; Cynthia Horn; Vânia Luiza Deperon Bonato
Journal:  Immunology       Date:  2007-04-13       Impact factor: 7.397

Review 5.  Vaccines for tuberculosis: novel concepts and recent progress.

Authors:  T Mark Doherty; Peter Andersen
Journal:  Clin Microbiol Rev       Date:  2005-10       Impact factor: 26.132

6.  The ID93 tuberculosis vaccine candidate does not induce sensitivity to purified protein derivative.

Authors:  Susan L Baldwin; Valerie Reese; Brian Granger; Mark T Orr; Gregory C Ireton; Rhea N Coler; Steven G Reed
Journal:  Clin Vaccine Immunol       Date:  2014-07-16

7.  Chlamydial protease-like activity factor mediated protection against C. trachomatis in guinea pigs.

Authors:  Shradha Wali; Rishein Gupta; Jieh-Juen Yu; Gopala Krishna Koundinya Lanka; James P Chambers; M Neal Guentzel; Guangming Zhong; Ashlesh K Murthy; Bernard P Arulanandam
Journal:  Immunol Cell Biol       Date:  2016-12-19       Impact factor: 5.126

Review 8.  Vaccines for COVID-19.

Authors:  J S Tregoning; E S Brown; H M Cheeseman; K E Flight; S L Higham; N-M Lemm; B F Pierce; D C Stirling; Z Wang; K M Pollock
Journal:  Clin Exp Immunol       Date:  2020-10-18       Impact factor: 4.330

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.